

3. Participants

Enter the Financial Officer and any Co-Principal Investigator, Co-Applicant, Additional Author and Collaborator information applicable to your application. Use the lookup feature and enter the participant's email address in the field provided as the search criteria. The form will be auto-populated with their contact information as it appears in their user profile. If they do not have a profile, enter the participant's details as required.

Please attach a CV for all participants (excluding the Financial Officer and Collaborators) and use the format:

[lastname_firstname-CV].

For collaborators, please attach the corresponding letter of support and use the format: [lastname_firstname-collaboration].

a. Additional Author

Name

Title

Institution

Department

Address 1

Address 2

Address 3

Address 4

Country

City

Province

Postal Code

Telephone

Fax

E-Mail Address

b. Co-Applicant

Name

Title

Institution

Department

Address 1

Address 2

Address 3

Address 4

Country

City

Province

Postal Code

Telephone

Fax

E-Mail Address

c. Collaborator

Name

Title

Institution

Department

Address 1

Address 2

Address 3

Address 4

Country

City

Province

Postal Code

Telephone

Fax

E-Mail Address

d. Co-Principal Investigator

Name

Title

Institution

Department

Address 1

Address 2

Address 3

Address 4

Country

City

Province

Postal Code

Telephone

Fax

E-Mail Address

e. Financial Officer

Name

Title

Institution

Department

Address 1

Address 2

Address 3

Address 4

Country

City

Province

Postal Code

Telephone

Fax

E-Mail Address

SAMPLE

Applicant info

4. Principal Investigator CV

Attach an up-to-date, abbreviated version of your CV in PDF format. Your CV should include your academic degrees and details of employment since graduation (maximum 3 pages in length), plus a list of your publications and grants in the past 5 years. Consult the Application Guide for complete instructions, including the required format. NOTE: For the file name, please use the following format:[lastname_firstname-CV].
CCS is not a member organization of the Common CV Network, therefore the Common CV should not be used due to Common CV use restrictions.

5. Application and Career stage

This section is mandatory and plays no part in the review or funding of an application. The data is used for statistical and communication purposes only.

Please indicate below if this is:

- | | | |
|---|---------------------------|--------------------------|
| Your first application for a research grant to the Canadian Cancer Society | <input type="radio"/> Yes | <input type="radio"/> No |
| Your first application for a research grant specifically in the area of cancer research | <input type="radio"/> Yes | <input type="radio"/> No |
| Your first application for a research grant as an independent investigator | <input type="radio"/> Yes | <input type="radio"/> No |

Please indicate your current career stage (please select one of the three options):

- New/early career investigator: Any applicant who, at the time of registration, assumed his/her first independent academic position (e.g., faculty appointment) no more than 5 years ago (60 months).
- Mid-career investigator: Any applicant who, at the time of registration, assumed his/her first independent academic position (e.g., faculty appointment) 5-15 years ago.
- Senior investigator: Any applicant who, at the time of registration, assumed his/her first independent academic position (e.g., faculty appointment) more than 15 years ago.

Certificates

6. Certificates required

6.a. Biohazard/Biosafety

Indicate if certificates will be required. Certificates will be requested at the time of funding.

- a. Does your project require a biohazard certificate? Yes No
- b. Are biohazard certificates required from other institutions (in case of Co-Principal Investigators and Co-Applicants)? Yes No
- c. If yes, give details.

| List of other institutions |
|----------------------------|
| |
| |
| |
| |
| |

6.b. Animal care

Indicate if certificates will be required. Certificates will be requested at the time of funding.

- a. Does your project require animal care certificates? Yes No
- b. Are animal care certificates required from other institutions (in case of Co-Principal Investigators and Co-Applicants)? Yes No
- c. If yes, give details.

| List of other institutions |
|----------------------------|
| |
| |
| |
| |
| |

6.c. Ethics

Indicate if certificates will be required. Certificates will be requested at the time of funding.

- a. Does your project require ethics certificates? Yes No
- b. Are ethics certificates required from other institutions (in case of Co-Principal Investigators and Co-Applicants)? Yes No
- c. If yes, give details.

| List of other institutions |
|----------------------------|
| |
| |
| |
| |
| |
| |
| |
| |

Public summary

8. Need for project

What need – in research or health care – will be addressed by this project (i.e. what is the rationale)? (maximum 500 characters, including spaces). Note that the character count may be different when copying text from Word due to formatting.

9. Goal of project

What is the goal of this project – what are you hoping to achieve? (maximum 500 characters, including spaces). Note that the character count may be different when copying text from Word due to formatting.

10. Project description

How will you achieve this (reminder: please use nontechnical language)? (maximum 500 characters, including spaces). Note that the character count may be different when copying text from Word due to formatting.

11. Future impact

How do you think this project could/will ultimately have an impact on the cancer community (including researchers, patients, families, policy, and the public at large, as relevant)? (maximum 650 characters, including spaces). Note that the character count may be different when copying text from Word due to formatting.

Abstract

12. Scientific abstract

Provide a detailed summary of your research project (maximum of 4200 characters, including spaces), stating the problem to be investigated, the objectives of the investigation, the methodology to be used, as well as the significance of the research to uterine carcinosarcoma and/or other aggressive uterine cancers. Note that the character count may be different when copying text from Word due to formatting.

13. Non-confidential scientific abstract

For applications approved for funding, a non-confidential scientific abstract will be posted along with the funding results on the CCS research webpage.
Please include a duplicate of your scientific abstract – with proprietary information removed. This abstract may also be shared with potential donors and CCS stakeholders when relevant. Your abstract should not exceed 4200 characters (including spaces), or roughly one full page, single spaced. Note that the character count may be different when copying text from Word due to formatting.

14. Keywords/Technical terms

Provide up to a maximum of ten specific keywords or descriptive technical terms/methodologies that best describe the scientific and technical aspects of your project. NOTE: Enter one keyword or technical term per line.

| Keyword/Technical terms |
|-------------------------|
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |

15. Uterine cancer and other aggressive uterine cancers relevance statement

The relevance statement (maximum of 2100 characters, including spaces) should explicitly describe how the project is relevant to uterine carcinosarcoma and/or other aggressive uterine cancers, particularly as it relates to the prevention, early detection, diagnosis, and/or treatment of these cancers. Research that is generally applicable to all or most cancer types does not qualify; there should be a marked focus on the unique features of uterine carcinosarcoma and/or other aggressive uterine cancers. Note that the character count may be different when copying text from Word due to formatting.

SAMPLE

19. Tables, graphs, charts and associated legends

OPTIONAL: Attach and appropriately label figures, tables, graphs, charts and legends in PDF format (maximum of 2 pages total). NOTE: For the file name, please use the following format: [lastname_firstname-figures].

20. List of references

Provide a list of references cited within the proposal. A standard reference style is recommended (e.g. first author, article title, journal title, date of publication, volume, issue, location (pagination))

21. Appendices

OPTIONAL: Note that all essential information must be included in the proposal and that reviewers are not required to read the material in the appendices. Attachments must be in PDF format only and can not exceed 10MB per attachment. NOTE: For the file name, please use the following format: [lastname_firstname-appendix1].

22. Disclosure of commercial or conflict of interest related to this application

If any of the named investigators have a financial interest in any commercial venture whose business activities are related to the subject matter of this grant application, the nature of that interest must be disclosed and a description of how conflict of interest, if any, will be managed should be provided. Please describe the nature of the relationship or material interest, the business activities of the company in question, and how those activities relate, if at all, to the grant application.

- a. Do applicants have any commercial or conflict of interest to declare? Yes No
- b. If Yes, please provide a description of the commercial or conflict of interest and how it will be managed.

Budget

| Description | 2020 | 2021 | Total |
|-------------------------------|------------------------------|------|-------|
| DIRECT EXPENSES | | | |
| Program Expenses | | | |
| 1 | Supplies and Expenses | | |
| 2 | Salaries and Wages | | |
| Total Program Expenses | 0.00 | 0.00 | 0.00 |
| Equipment | | | |
| 1 | Permanent Equipment | | |
| Total Equipment | 0.00 | 0.00 | 0.00 |
| TOTAL DIRECT EXPENSES | 0.00 | 0.00 | 0.00 |
| TOTAL EXPENDITURES | 0.00 | 0.00 | 0.00 |

Budget summary for Uterine Carcinosarcoma and other Aggressive Uterine Cancer Research Grant-2020

| Description | 2020 | 2021 | Total |
|-----------------------------------|-------------|-------------|-------------|
| Program Expenses | | | |
| Supplies and Expenses | 0.00 | 0.00 | 0.00 |
| Salaries and Wages | 0.00 | 0.00 | 0.00 |
| Total for Program Expenses | 0.00 | 0.00 | 0.00 |
| Permanent Equipment | 0.00 | 0.00 | 0.00 |
| TOTALS | 0.00 | 0.00 | 0.00 |

SAMPLE

Other funding

25. Summary of other funding applied for and received

List all grants currently being applied for, pending, about to be submitted and all grants received, for the entire period covered by this application, for the Principal Investigator and each Co-Principal Investigator. Your documentation should include a list followed by the abstracts/summaries, as submitted in the original application for funding, for all grants/applications listed and should be submitted in PDF format. For pending grant applications with similar titles, please include a statement explaining overlap, or lack thereof. Consult the Application Guide for complete instructions, including the correct format. If there are no pending grants to list, indicate by including N/A in the Pending grants section. Applications with missing other funding information or abstracts will be considered incomplete.

NOTE: For the file name, please use the following format: [lastname_firstname-other_funding]

26. Other funding confirmation

- The applicants confirm that the attached list contains all required information, including the percentage overlap for each grant and the abstracts as submitted in the original application for funding, as described in the Application Guide.

SAMPLE

Review panel

27. Panel

Review Panel

Uterine Cancer Research Grants Panel

28. Reviewer recommendation

Applicants must suggest the names of at least 3 (5 if submitting application in French) impartial reviewers with the necessary expertise to critically evaluate the application and with whom you do NOT collaborate.

| Name | Department | Institution | Phone no. | E-mail address | Areas of expertise |
|------|------------|-------------|-----------|----------------|--------------------|
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

29. Reviewer exclusions

Applicants may suggest individuals they prefer NOT be contacted as potential reviewers (panel members and/or external reviewers). The reason for exclusion (e.g. collaborator, colleague, competitor) should be given.

| Name | Reason for exclusion |
|------|----------------------|
| | |
| | |
| | |
| | |
| | |

Biographical information

30. Biographical information

While completion of this section is mandatory, responses will be strictly confidential and will not be shared with the review panel. Aggregated and anonymized data will be used for program administration, statistical reporting and communications purposes only.

Preferred pronoun

He/His

She/Her

They/Their

Prefer not to respond

Language(s) spoken

Citizenship

SAMPLE

Tracking

31. Research tracking information

Responses are to be limited to the scope of the proposed research for the duration of the proposed term. This information is used solely for statistical/reporting purposes and will not be used as part of the scientific review of the application. Select the research focus of the proposal.

31.a. Research focus

Responses are to be limited to the scope of the proposed research for the duration of the proposed term. This information is used solely for statistical/reporting purposes and will not be used as part of the scientific review of the application. Select the research focus of the proposal.

I. SECTION I - Research focus (select ONE only)

Biomedical Research

Clinical Research

Health Services/Systems Research

Social, Cultural, Environmental and Population Health

31.b. Research subject

Select the research subject(s).

II. SECTION II - Research subject (select ONE or MORE)

Patients/Study Population

Adult

Pediatric

Adolescents & Young Adults

Patient Tissue

Adult

Pediatric

Adolescents & Young Adults

Model System

Mouse

Drosophila

C. elegans

Zebrafish

Yeast

Other

Cell System

hESC

Tumour Initiating Cell

Non-embryo-derived stem cells (eg. iPS cells)

31.c. Cancer site relevance

Select a maximum of 3 cancer sites where the research will be most relevant. Indicate the degree of relevance (percentage). The total should equal 100%. Only use the Details description field to describe the site if you have selected Other as a site.

Note: Do not enter a % sign with your percentage, only enter the number.

III. SECTION III - Cancer site relevance

| Cancer site relevance | Percentage | Details |
|-----------------------|------------|---------|
| | | |
| | | |
| | | |

31.d. Common Scientific Outline (CSO)

Select a maximum of 3 codes which best describe the research. Full details of the Common Scientific Outline can be found at the International Cancer Research Portfolio website (<https://www.icrpartnership.org/cso>).

IV. **Section IV - Common Scientific Outline (CSO)****Biology**

- 1.1 Normal functioning
- 1.2 Cancer initiation: alterations in chromosomes
- 1.3 Cancer initiation: oncogenes and tumour suppressor genes
- 1.4 Cancer progression and metastasis
- 1.5 Resources and infrastructure

Etiology

- 2.1 Exogenous factors in the origin and cause of cancer
- 2.2 Endogenous factors in the origin and cause of cancer
- 2.3 Interactions of genes and/or genetic polymorphisms with exogenous and/or endogenous factors
- 2.4 Resources and infrastructure related to etiology

Prevention

- 3.1 Interventions to prevent cancer: personal behaviors (non-dietary) that affect cancer risk
- 3.2 Dietary interventions to reduce cancer risk and nutritional science in cancer prevention
- 3.3 Chemoprevention and other medical interventions
- 3.4 Vaccines
- 3.5 Complementary and alternative prevention approaches
- 3.6 Resources and infrastructure related to prevention

Early Detection, Diagnosis and Prognosis

- 4.1 Technology development and/or marker discovery
- 4.2 Technology and/or marker evaluation with respect to fundamental parameters of method
- 4.3 Technology and/or marker testing in a clinical setting
- 4.4 Resources and infrastructure related to detection, diagnosis and prognosis

Treatment

- 5.1 Localized therapies – discovery and development
- 5.2 Localized therapies – clinical applications
- 5.3 Systemic therapies – discovery and development
- 5.4 Systemic therapies – clinical applications
- 5.5 Combinations of localized and systemic therapies
- 5.6 Complementary and alternative treatment approaches
- 5.7 Resources and infrastructure related to treatment and the prevention of recurrence

Cancer Control, Survivorship and Outcomes Research

- 6.1 Patient care and survivorship issues
- 6.2 Surveillance
- 6.3 Population-based behavioral factors
- 6.4 Health services, economic and health policy analyses
- 6.5 Education and communication research
- 6.6 End-of-life care
- 6.7 Research on ethics and confidentiality
- 6.8 Historical code - no longer used
- 6.9 Resources and infrastructure related to cancer control, survivorship and outcomes research

Release form

32. Release form

The CCS depends on donor dollars to fund its grants. Applicants must declare their willingness to allow CCS to provide minimal details of their grant to potential donors/partners. For successful investigators, the grantee must declare their understanding that CCS will post competition results (PI, HI, title, value of grant, lay summary) on our website and potentially include a lay summary of the progress and impact of the research in our reports to donors/the public, press releases, social media or other communications.

On condition that:

- the specified information will be shared by CCS only with potential donors/partners and for the sole purpose of obtaining additional funding for CCS's grant competitions.
 - potential donors/partners will be required to declare conflict of interest, and sign a confidentiality agreement before the specified information is released to them by CCS.
 - it will be held confidential by them and not released to other parties, and will be returned to CCS or destroyed if the decision is not to fund.
 - all information released may be retained by the potential donors/partners if it decides to fund the application, and may be used by the donor/partner in its funding announcements and other communications.
- I acknowledge the sharing of the information specified with potential donors/partners and if successful in the competition, CCS will announce the grant and may publish research impacts (described above).

Head of Department

33. Head of Department/Dean confirmation

This section can only be completed by the Head of the applicant's research department. If the project is to be carried out by the Head of the Department the application must instead be confirmed by the Dean. As the Head of Department/Dean your online acknowledgement indicates that you are aware of the contents of the application being submitted. Answer the question below, then click on Save to complete your confirmation.

I confirm that I am aware of the contents of the application being submitted.

Yes No

Name of the Head of Department or Dean

Title

Research Institution

Financial Institution

Date

| |
|--|
| |
| |
| |
| |
| |

SAMPLE

Executive authority - research host

34. Executive authority of the host research institution

This section can only be completed by an executive authority of the Host Institution within which the research will be conducted. As the Executive Authority your online acknowledgement indicates that you have read and understood the Terms of the Host Institution/CCS Agreement. Answer the question below, then click on Save to complete your confirmation.

I confirm that I have read and understood the Host Institution / CCS Agreement and agree to abide by the terms. Yes No

Name of the Executive Authority - research host

Title

Research Institution

Financial Institution

Date

| |
|--|
| |
| |
| |
| |
| |

SAMPLE

Executive authority - financial host

35. Executive authority of the host finance institution

This section can only be completed by an executive authority of the Institution within which the funds will be administered. As the Executive Authority your online acknowledgement indicates that you have read and understood the Terms of the Host Institution/CCS Agreement. Answer the question below, then click on Save to complete your confirmation.

I confirm that I have read and understood the Host Institution / CCS Agreement, and Yes No
agree to abide by the terms.

Name of the Executive Authority - financial host

Title

Research Institution

Financial Institution

Date

| |
|--|
| |
| |
| |
| |
| |

SAMPLE

Post submission publications

36. Post submission publications

Publication lists included in this section prior to submission will be removed. This section should only be used after you have submitted your application. Attach a PDF document of your acceptance e-mail/letter for newly accepted publications. You may update this attachment at any time after you've submitted your application, up until the panel meeting. NOTE: For the file name, use the following format [lastname_firstname_publications_yyyymmdd], where yyyymmdd is the current date.

SAMPLE